LAMATTINA JOHN L sold 14.5% of their position (4.59K shares) of LIGAND PHARMACEUTICALS INC on the open market
Open‑market sale worth $1.15M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 6/12/2026ACC: 0002001011-26-000102
Director
Since Sep 2018
-4.59K
Net shares
Net seller
$1.15M
Total sold
4
Open market trades
0B · 4S
4
Total transactions
4.59K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−257.00
Price / share
$247.22
Trade value
$63.54K
% of position
0.8%
6/10/2026
31.56K→31.30K
Common Stock
Direct
Shares
−232.00
Price / share
$248.11
Trade value
$57.56K
% of position
0.7%
6/10/2026
31.30K→31.07K
Common Stock
Direct
Shares
−697.00
Price / share
$249.53
Trade value
$173.92K
% of position
2.2%
6/10/2026
31.07K→30.37K
Common Stock
Direct
Shares
−3.40K
Price / share
$251.62
Trade value
$856.75K
% of position
11.2%
6/10/2026
30.37K→26.97K
Total
Net shares
−4.59K
Net value
-$1.15M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/10/2026 | S · Sale | −257.00 | $247.22 | $63.54K | 0.8% | 31.56K | 31.30K |
| Common Stock Direct | 6/10/2026 | S · Sale | −232.00 | $248.11 | $57.56K | 0.7% | 31.30K | 31.07K |
| Common Stock Direct | 6/10/2026 | S · Sale | −697.00 | $249.53 | $173.92K | 2.2% | 31.07K | 30.37K |
| Common Stock Direct | 6/10/2026 | S · Sale | −3.40K | $251.62 | $856.75K | 11.2% | 30.37K | 26.97K |
| Total | −4.59K | -$1.15M | ||||||
Derivative Transactions0
No derivative transactions reported